Tim3.KD.MSLN-CAR T cells

Tim3.KD.MSLN-CAR T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy genetically engineered to express a CAR targeting **mesothelin (MSLN)**, a tumor-associated antigen overexpressed in various solid tumors (such as mesothelioma, ovarian, and pancreatic cancers). These cells are further modified with knockdown (KD) of **Tim3**, an immune checkpoint molecule (T cell immunoglobulin and mucin domain-containing protein 3) implicated in T cell exhaustion. The aim is to improve the efficacy and persistence of CAR T cell therapy by preventing Tim3-mediated inhibitory signaling. The therapy is under early-phase clinical and preclinical evaluation, primarily for **MSLN-positive solid tumors**. The cells are generated autologously: patient T cells are harvested, genetically engineered (typically with viral vectors), expanded, and administered via infusion as a cell therapy to attack MSLN-expressing tumor cells.